We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 12 juli 2018

The Lancet: [Comment] Non-invasive image-guided targeted drug delivery

[Comment] Non-invasive image-guided targeted drug delivery
Actively targeted and triggered drug delivery systems to enhance tumour drug uptake—such as liposomes and other nanoparticles—have been the subject of intensive research for several decades, but so far have not shown therapeutic benefit in clinical trials.1 In The Lancet Oncology, Paul C Lyon and colleagues report for the first time in humans the ability to non-invasively enhance drug delivery by triggered chemotherapy release from heat-activated liposomes, while also suggesting a therapeutic response to this enhanced delivery.
Read more

[Articles] Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial
The combined treatment of LTLD and non-invasive focused ultrasound hyperthermia in this study seemed to be clinically feasible, safe, and able to enhance intratumoural drug delivery, providing targeted chemo-ablative response in human liver tumours that were refractory to standard chemotherapy.
Read more

[Articles] Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
Pazopanib oral suspension at a dose of 800 mg/day was feasible to administer in combination with standard weekly cetuximab for patients with recurrent or metastatic HNSCC. Encouraging preliminary antitumour activity was observed with this combination therapy and warrants further validation in randomised trials.
Read more

[Articles] Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar functional outcomes at 24 months. We advise caution in interpreting the oncological outcomes of our study because of the absence of standardisation in postoperative management between the two trial groups and the use of additional cancer treatments. Clinicians and patients should view the benefits of a robotic approach as being largely related to its minimally invasive nature.
Read more

[News] Systemic therapy after IFRT for follicular lymphoma
Findings from a randomised, controlled study showed that systemic therapy including rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) improves progression-free survival following involved-field radiation therapy (IFRT) compared with IFRT alone in patients with early-stage follicular lymphoma.
Read more